Cantor Fitzgerald Reiterates “Overweight” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued on Tuesday,Benzinga reports. They currently have a $163.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 103.83% from the company’s previous close.

A number of other research analysts have also commented on the company. Royal Bank of Canada decreased their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Scotiabank started coverage on Sarepta Therapeutics in a research report on Friday, March 7th. They issued a “sector perform” rating and a $105.00 price objective on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on Sarepta Therapeutics in a research report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Finally, StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average price target of $168.55.

Sarepta Therapeutics Trading Up 8.7 %

SRPT stock opened at $79.97 on Tuesday. The business has a fifty day moving average price of $109.26 and a 200 day moving average price of $118.86. Sarepta Therapeutics has a fifty-two week low of $73.06 and a fifty-two week high of $173.25. The stock has a market capitalization of $7.76 billion, a price-to-earnings ratio of 63.98 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SRPT. Sumitomo Mitsui Trust Group Inc. raised its stake in Sarepta Therapeutics by 21.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,700 shares of the biotechnology company’s stock valued at $212,000 after buying an additional 300 shares during the period. Oppenheimer Asset Management Inc. grew its position in shares of Sarepta Therapeutics by 3.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after purchasing an additional 145 shares during the last quarter. Huntington National Bank grew its position in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the last quarter. CIBC Asset Management Inc grew its position in shares of Sarepta Therapeutics by 3.3% in the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after purchasing an additional 86 shares during the last quarter. Finally, Commerce Bank grew its position in shares of Sarepta Therapeutics by 15.7% in the third quarter. Commerce Bank now owns 2,016 shares of the biotechnology company’s stock valued at $252,000 after purchasing an additional 274 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.